BNTC
Benitec Biopharma Inc.
Next earnings Sep 21, 2026 (after close) · consensus $-0.29 EPS
Last earnings +1.7% on 2026-05-14
$12.37
▼ -4.85%$12.37▼ -15.10%
over 1Y
L $10.06EODHDH $16.52
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-4.8%
1W+0.6%
1M+6.6%
3M+20.4%
YTD-1.7%
1Y-15.1%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 13 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.02x); but revenue fell -100.0% YoY.
Revenue (FY2024) $0.00 · FY2024
Benitec Biopharma Inc. shows $0.00 in FY2024 revenue (-100.0% YoY), and -39.0% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $59.0K | $73.0K | $75.0K | $0.00 | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$13.6M | -$17.9M | -$19.1M | -$22.5M | -$41.8M |
| Net income | -$13.9M | -$18.2M | -$19.6M | -$21.8M | -$37.9M |
| Diluted EPS | -$3.23 | -$37.88 | -$14.12 | -$1.22 | -$1.05 |
| Net margin | -23528.8% | -24942.5% | -26082.7% | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$227M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-11.7%
FCF yield-7.3%
Quality & risk
ROIC (est.)-33.9%
Free cash flow-$23.6M
Total debt—
Net cash$97.7M
Altman Z-Score81.39 safe
Piotroski F-Score3/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+148.7%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — restated periodic report (2026-03-20). Worth a closer look.
- 8-K Officer / director change2026-05-29
- 8-K Earnings results2026-05-14
- 10-Q Quarterly report2026-05-14
- 10-K/A Restated periodic report2026-03-20
- 8-K Earnings results2026-02-12
- 10-Q Quarterly report2026-02-12
- S-3 Shelf registration (potential raise)2026-01-30
- 8-K Shareholder vote2025-12-02
- 8-K Earnings results2025-11-14
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-05-222026-05-29open ↗4Period ending 2026-05-262026-05-28open ↗3Period ending 2026-05-222026-05-28open ↗10-QPeriod ending 2026-03-312026-05-14open ↗8-KPeriod ending 2026-05-142026-05-14open ↗10-K/APeriod ending 2025-06-302026-03-20open ↗8-KPeriod ending 2026-02-122026-02-12open ↗10-QPeriod ending 2025-12-312026-02-12open ↗424B3Filing2026-02-11open ↗EFFECTFiling2026-02-10open ↗CORRESPFiling2026-02-06open ↗UPLOADFiling2026-02-06open ↗
Frequently asked
- Is Benitec Biopharma Inc. (BNTC) a buy?
- BNTC currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.02x); but revenue fell -100.0% YoY.
- What is Benitec Biopharma Inc.'s quality score?
- BNTC scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001808898, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 7:29:16 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.